By Anthony O. Goriainoff

 

GSK PLC said Friday that its respiratory syncytial virus, or RSV, vaccine candidate showed a statistically significant and clinically meaningful efficacy in adults aged 60 and over.

The London-listed pharmaceutical company said an efficacy analysis of the AReSVi 006 Phase 3 trial showed it offered exceptional protection for older adults from the serious consequences of RSV infection.

The company said it would start to engage with regulators immediately and that it expected regulatory submissions in the second half of the year.

"The AReSVi 006 trial will continue to evaluate both an annual revaccination schedule and longer-term protection over multiple seasons following one dose of the RSV older adult vaccine candidate," the company said.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

June 10, 2022 02:29 ET (06:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Gsk Charts.